Clinical trial registry record

First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Not Yet Recruiting.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 18, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07766473
Last registry update
September 18, 2026
Status
Not Yet Recruiting
Phase
Phase 1, Phase 2
Sponsor
Filamon LTD
Enrollment
24
Countries
Australia
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
24
Population
ALL · 50 Years
Duration
2026-09-01 to 2027-09-01
Intervention
BETA-TT8 ophthalmic gel 3.8% w/v
Comparator
BETA-TT8 Ophthalmic topical gel - Group one; BETA-TT8 Ophthalmic topical gel - Group two; BETA-TT8 Ophthalmic topical gel - Group three
Outcomes measured
To evaluate the safety of topical BETA-TT8 based on TEAEs. — 12 weeks; To evaluate the safety of topical BETA-TT8 based on DLTs. — 12 weeks; To evaluate the safety of topical BETA-TT8 based on clinically significant ocular findings. — 12 weeks; To evaluate the safety of topical BETA-TT8 based on intraocular pressure changes. — 12 weeks; To evaluate the safety of topical BETA-TT8 based on corneal staining abnormalities. — 12 weeks; To evaluate the tolerability of topical BETA-TT8 based on reasons for discontinuations. — 12 weeks; To further characterise ocular safety following repeated topical administration based on preliminary biological activit…; Exploratory-efficacy signals during BETA-TT8 treatment phase. — 12 weeks
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON